The Tailored EDVTM trial: A phase I feasibility study evaluating EGFR-targeted EDVTM nanocells as a therapy platform in patients with refractory advanced solid tumours

被引：1
|
作者：
Clarke, S. [1 ]
Sidhu, S. [2 ]
Pavlakis, N. [1 ]
Brahmbhatt, H. [3 ]
Macdiarmid, J. [3 ]
机构：
[1] Univ Sydney, Northern Canc Inst, Sydney, NSW, Australia
[2] Univ Sydney, Endocrine Surg Unit, Sydney, NSW, Australia
[3] EnGeneIC, Biotechnol, Sydney, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw368.55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
412TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
    Iguchi, Haruo
    Nishina, Tomohiro
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Yamagiwa, Yumiko
    Yagawa, Katsuro
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 194 - 200
  • [32] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours.
    Agus, D. B.
    Terlizzi, E.
    Stopfer, P.
    Amelsberg, A.
    Gordon, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 97S - 97S
  • [33] Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer.
    Lundy, Joanne
    Marx, Gavin M.
    MacDiarmid, Jennifer
    Brahmbhatt, Himanshu
    Ganju, Vinod
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Supko, Jeffrey G.
    Cho, Daniel C.
    Hilton, John Frederick
    Hadfield, Matthew
    Pruitt-Thompson, Salida
    Bordoli-Trachsela, Eveline
    Zvereva, Nela
    Wolanski, Andrew
    Sato-DiLorenzo, Aya
    Gotthardt, Susan
    Fox, Edward A.
    Verselis, Sigitas Jonas
    Kumar, Ashok
    Holden, Sylvia A.
    Ram, Siya
    Chafai-Fadela, Karima
    Harding, Kimberly
    Menon, Krishna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] The phase I INSIGHT platform trial: Safety data from stratum D of evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced stage solid tumor entities
    Goetze, T. O.
    Mueller, D. W.
    Rafiyan, M. -R.
    Kiselicki, D.
    Habibzade, T.
    Schaaf, M.
    Eickhoff, R.
    Jaeger, E.
    Al-Batran, S. -E.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 232 - 233
  • [36] A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy.
    Chiang, Nai-Jung
    Shiah, Her-Shyong
    Lin, Chia-Chi
    Yen, Chia-Jui
    Tsai, Hui-Jen
    Wu, Shang-Yin
    Su, Wu-Chou
    Chang, Kwang-Yu
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Phase I adoptive cellular therapy trial with actively personalized, multi-targeted CD8+T-cells in patients with relapsed and/or refractory solid cancers (ACTologIMA101-101)
    Ma, Hong
    Kuttruff, Sabrina
    Stewart, Chad
    Bulliard, Yannick
    Stephens, Geoffrey
    Schoor, Oliver
    Satelli, Arun
    Hilf, Norbert
    Sieger, Kerry
    Fritsche, Jens
    Maurer, Dominik
    Mohamed, Ali
    Weinschenk, Toni
    Reinhardt, Carsten
    Walter, Steffen
    Singh, Harpreet
    Hwu, Patrick
    Yee, Cassian
    Andersson, Borje
    Tsimberidou, Apostolia-Marie
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
    Soria, Jean-Charles
    Baselga, Jose
    Hanna, Nasser
    Laurie, Scott A.
    Bahleda, Rastislav
    Felip, Enriqueta
    Calvo, Emiliano
    Armand, Jean-Pierre
    Shepherd, Frances A.
    Harbison, Christopher T.
    Berman, David
    Park, Jong-Soon
    Zhang, Steven
    Vakkalagadda, Blisse
    Kurland, John F.
    Pathak, Ashutosh K.
    Herbst, Roy S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (08) : 1815 - 1824
  • [39] Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumour entities
    Goetze, T. O.
    Mueller, D. W.
    Rafiyan, M-R.
    Kiselicki, D.
    Habibzade, T.
    Eickhoff, R.
    Jaeger, E.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2020, 31 : S712 - S712
  • [40] A phase I, multicenter, open-label dosimetry study of I-131-CLR1404 in patients with relapsed or refractory advanced solid tumors who have failed standard therapy or for whom no standard therapy exists.
    Chao, Joseph
    Mortimer, Joanne E.
    Cho, Steve Y.
    Marshall, John
    Wong, Terence
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345